(Reuters) - ISTA's shares fell 19 percent in pre-market electronic trade to $7.80, after closing at $9.62 Thursday on the Nasdaq.
The U.S. Food and Drug Administration did not find sufficient clinical information to approve the drug, the company said, an assessment it disagrees with.
Read more at Reuters.com Government Filings News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment